Comparator: timolol — Competitive Intelligence Brief

Comparator: timolol (Comparator: timolol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-adrenergic antagonist (non-selective beta-blocker). Area: Ophthalmology.

phase 3 Beta-adrenergic antagonist (non-selective beta-blocker) Beta-1 and beta-2 adrenergic receptors Ophthalmology Small molecule

Target snapshot

Comparator: timolol (Comparator: timolol) — Merck Sharp & Dohme LLC. Timolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Comparator: timolol TARGET	Comparator: timolol	Merck Sharp & Dohme LLC	phase 3	Beta-adrenergic antagonist (non-selective beta-blocker)	Beta-1 and beta-2 adrenergic receptors
RASi plus carvedilol	RASi plus carvedilol	Federal University of Minas Gerais	marketed	ACE inhibitor or ARB combined with non-selective beta-blocker	Angiotensin II receptor / ACE enzyme; beta-1 and beta-2 adrenergic receptors; alpha-1 adrenergic receptor
treatment with brimonidine/timolol	treatment with brimonidine/timolol	Aristotle University Of Thessaloniki	marketed	Alpha-2 adrenergic agonist / Beta-blocker combination	Alpha-2 adrenergic receptor; Beta-1 and Beta-2 adrenergic receptors
Timolol 0.5% Ophthalmic Solution	Timolol 0.5% Ophthalmic Solution	University of California, Davis	marketed	Beta-adrenergic antagonist	Beta-1 and beta-2 adrenergic receptors
tafluprost and dorzolamide/timolol	tafluprost and dorzolamide/timolol	Aristotle University Of Thessaloniki	marketed	Prostaglandin analogue / carbonic anhydrase inhibitor / beta-blocker combination	Prostaglandin F receptor (FP receptor), carbonic anhydrase II, beta-1 and beta-2 adrenergic receptors
amiodarone beta blocker sotalol	amiodarone beta blocker sotalol	Connolly, Stuart, M.D.	marketed	Beta-blocker with Class III antiarrhythmic activity	Beta-1 and beta-2 adrenergic receptors; potassium channels (IKr)
betablocker titration	betablocker titration	Policlinico Casilino ASL RMB	marketed	Beta-adrenergic antagonist	Beta-1 and beta-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-adrenergic antagonist (non-selective beta-blocker) class)

1. Keith G. LeBlanc, Jr, MD · 1 drug in this class
2. Merck Sharp & Dohme LLC · 1 drug in this class